P2318
Anti-Pseudomonas Exotoxin A antibody produced in rabbit
whole antiserum
Synonym(s):
Anti-ETA
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
whole antiserum
antibody product type
primary antibodies
clone
polyclonal
contains
15 mM sodium azide
species reactivity
(Pseudomonas aeruginosa)
technique(s)
dot blot: 1:20,000
indirect ELISA: 1:250,000
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
Pseudomonas aeruginosa PAO1 ... toxA(877850)
General description
Reacts against Pseudomonas exotoxin A, but shows no reaction against Staphylococcal enterotoxin A, Cholera toxin, and Staphylococcal enterotoxin B. The product has not been tested for neutralization potency against active Pseudomonas exotoxin A.
Immunogen
exotoxin A from Pseudomonas aeruginosa.
Application
Anti-Pseudomonas Exotoxin A antibody has been used in in vitro serum stability of fusion toxins and binding of targeted toxins.
Anti-Pseudomonas exotoxin A antibody produced in rabbit has been used:
- in the in vitro analysis of the stability of fusion toxins in serum
- to construct an epidermal growth factor receptor (EGFR)-targeted toxin to study its toxicity on Swiss mouse embryo NIH-3T3 cells transfected with human EGFR
- in the determination of the in vivo half-life of immunotoxins in serum
Biochem/physiol Actions
Pseudomonas exotoxin A is secreted by Pseudomonas aeruginosa and has potent cytotoxic effects. Exotoxin A enters the cells by receptor-mediated endocytosis, translocates to the cytoplasm and inhibits protein synthesis by ADP-ribosylating factor 2. Chimeric exotoxin A has applications in gene treatment of various diseases and probable treatment for cancer.
Physical form
This product is supplied as a liquid containing 15 mM sodium azide as preservative.
Preparation Note
For continuous use, store at 2-8 °C for up to one month. For extended storage, the solution may be frozen in working aliquots. Repeated freezing and thawing is not recommended. Storage in "frost-free" freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins
Weng A, et al.
Molecular Oncology, 6(3), 323-332 (2012)
Mark Kowalski et al.
Drug design, development and therapy, 4, 313-320 (2010-12-15)
A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer (NMIBC) refractory to or intolerant of bacillus Calmette-Guerin (BCG). Secondary objectives included evaluation of the safety
Alexander Weng et al.
Molecular oncology, 6(3), 323-332 (2012-02-09)
Tumor-targeting protein toxins are composed of a toxic enzyme coupled to a specific cell binding domain that targets cancer-associated antigens. The anti-tumor treatment by targeted toxins is accompanied by dose-limiting side effects. The future prospects of targeted toxins for therapeutic
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Guo R, et al.
International Journal of Pharmaceutics, 511(1), 538-549 (2016)
Chao Pan et al.
mBio, 7(2), e00443-e00416 (2016-04-28)
Conjugate vaccines are known to be one of the most effective and safest types of vaccines against bacterial pathogens. Previously, vaccine biosynthesis has been performed by using N-linked glycosylation systems. However, the structural specificity of these systems for sugar substrates
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service